Filing Flows › Standard Biotools (LAB) › Q2 2026 › vs Q2 2025
Standard Biotools (LAB) Q2 2026 vs Q2 2025 (year over year)
Standard Biotools's revenue fell $1.7M (-8%) from $21.8M in Q2 2025 to $20.1M in Q2 2026. The biggest changes: Product −$1.2M (-7%); Services and Other Revenue −$500K (-8%).
Standard Biotools, Q2 2026: revenue $20.1M (-8% year over year), operating margin -126.3%, net loss $26.8M, operating cash flow −$10.3M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Consumables | $9.4M | $10.5M | −$1.1M | -10% |
| Instruments | $5.1M | $5.2M | −$85K | -2% |
| Product | $14.5M | $15.7M | −$1.2M | -7% |
| Services and Other Revenue | $5.6M | $6.1M | −$500K | -8% |
| Revenue | $20.1M | $21.8M | −$1.7M | -8% |
| Net loss | $26.8M | $33.5M | −$6.7M | -20% |
| Costs & expenses | $46.9M | $55.8M | −$9.0M | -16% |
| Operating costs | $45.5M | $47.5M | −$2.0M | -4% |
| Interest & other, net | $1.3M | $8.4M | −$7.1M | -85% |
| Income tax | $90K | −$609K | $699K | — |
| Cost of revenue | $9.6M | $11.1M | −$1.6M | -14% |
| Research & development | $2.0M | $6.2M | −$4.2M | -68% |
| SG&A | $16.4M | $28.1M | −$11.7M | -42% |
| Other operating costs | $17.6M | $2.0M | $15.6M | +779% |
| Operating cash sources | $26.8M | $33.5M | −$6.7M | -20% |
| Depreciation & amortization | $1.3M | $3.2M | −$1.9M | -60% |
| Share-based compensation | $4.0M | $6.4M | −$2.3M | -37% |
| Working capital & other | $11.1M | $3.2M | $7.9M | +245% |
| Cash used in operations | $10.3M | $20.7M | −$10.4M | -50% |
| Net loss absorbed | $26.8M | $33.5M | −$6.7M | -20% |
Questions
How much did Standard Biotools's revenue grow year over year in Q2 2026?
Standard Biotools's revenue fell $1.7M (-8%) from $21.8M in Q2 2025 to $20.1M in Q2 2026.
What drove Standard Biotools's revenue change in Q2 2026?
Product −$1.2M (-7%); Services and Other Revenue −$500K (-8%).